← Back to Calendar
Indication
Cardiology — Chicago, IL
Key Notes
ACC Scientific Sessions 2026: March 28–30, Chicago. Conference completed. Key presentations included: MYQORZO (aficamten) real-world commercial launch data and early market uptake vs Camzyos; ACACIA-HCM (non-obstructive HCM) interim data from Cytokinetics. MAPLE-HCM sNDA review timeline reaffirmed for Q4 2026 PDUFA.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.